Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1654 for Prevention of RSV Lower Respiratory Tract Infection in Infants (Phase III, China Substudy)
CTR20221857Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of clesrovimab-cfor in respiratory syncytial virus disease (RSV), acute lower respiratory tract infection (LRTI), sponsored by Merck & Co.. Started Jul 2022; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus disease (RSV)acute lower respiratory tract infection (LRTI)
Beyond the preview
Go deeper on CTR20221857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221857.